PDCD1 and glioma: Currently, an inhibitor of the T-lymphocyte-associate antigen 4 (CTLA-4) and six inhibitors of the programmed cell death protein pathway (PD-1/PD-L1) have received regulatory approval from US Food and Drug Administration (FDA) for different cancer types, but not in gliomas [126].